Surfing the MASH Tsunami

Send us Fan Mail In 2024, the two major areas for change in diagnosing and treating MASH  are new drug approval and changes in use of NITs. Naim Alkhouri and Ian Rowe join Jörn Schattenberg, Louise Campbell and Roger Green to consider what might change with NITs and how having an approved drug might change thinking on this issue. 00:00:00 - Surf's Up: Season 5 Episode 5 Opening introduction,...

Send us Fan Mail Two years ago,  Surfing the MASH Tsunami conducted two episodes with Chris Estes, then the chief modeler for the Center for Disease Analysis Foundation exploring issues around CDAF's then-recent publication of a NASH/MASH disease model. This conversation centers on issues of advanced fibrosis. We thought it might be interesting to look back at that episode in lieu of today&ap...

Send us Fan Mail As the episode comes to an end, the group winds up focusing on the need for better, more frequent MASH education as a pivotal need if we are to flatten the growth curve of the MASLD pandemic. In the process, the discussion returns to the risk for women and the important role they can play.  Louise Campbell starts this conversation by harkening back to the issue of post-menopausal...

Send us Fan Mail This conversation focuses largely on the work of the Global NASH Council, an effort of over 200 stakeholders in more than 50 countries to address a range of macro issues in the MASLD space. Zobair Younossi, who is the Global NASH Council Chair, starts this conversation by discussing a specific Global NASH Council project on how to implement guidelines for different specialties acr...

Send us Fan Mail In this opening conversation on MASLD disease burden, Zobair Younossi summarizes and expands on some key points from the recent Diabetes Spectrum review article he co-authored with Linda Henry. Zobair starts by discussing the recent review article, Understanding the Burden of Non-Alcoholic Fatty Liver Disease: Time for Action which he describes as "a summary of a large body o...

Send us Fan Mail Initially, this conversation focuses on how cost-effectiveness issues relate to the MASLD Disease Burden. In the process, Zobair Younossi provides education on some of the metrics and concepts pivotal to drug value assessment. Roger Green starts off asking how the economics of treating MASH stack up against hypercholesterolemia at the birth of statins in the 1980s, where the medic...

Send us Fan Mail This conversation starts with a focus on slowing the growth of the MASLD pandemic, and then veers slightly into a discussion of the specific issues post-menopausal women face with MASLD.  Roger Green starts by commenting how it seems both pivotally important and highly efficient to find a way to flatten the growth curve, and he asks Zobair what he considers key to doing so.  Zobai...

Send us Fan Mail Zobair Younossi, Chair of the Global NASL Council, publishes seminal papers  on MASLD epidemology, cost of disease, and related public health needs regularly. Co-hosts Jörn Schattenberg, Louise Campbell, and Roger Green ask questions and share perspectives from their own experiences. 00:00:00 - Surf's Up: Season 5 Episode 4 Opening introduction, including brief quotes taken d...

Send us Fan Mail Our first conversation focusing on the new MASLD nomenclature surfaces as part of our coverage of the EASL Congress 2023. Hepatology researchers and key opinion leaders Sven Francque and Ian Rowe joined Jörn Schattenberg and Roger Green to discuss the value of the new nomenclature and its current and anticipated impact on their practices.  This conversation focuses on the outcome...

Send us Fan Mail This conversation ties up several issues related to MASH and the new MASLD nomenclature that the panel did not touch on earlier in the episode. These range from the impact the nomenclature might have on other elements of treatment to the impact of this effort over time. Finally, the panelists grade the process to date (they admit, their views might be a bit biased) and signs of su...

Send us Fan Mail This conversation focuses on how the new MASLD nomenclature might improve providers' explanations of MASH to patients. Louise Campbell describes new opportunities, while Meena Bansal describes how focusing on metabolism provides a richer opportunity for providers to explain to MASH patients why fat on the liver matters. Louise Campbell starts this conversation by discussing a...

Send us Fan Mail This conversation shifts from the rearview to the path ahead. Louise Campbell starts by asking about the role of Allied Health Providers in the process. After this issue, process leaders Maru Rinella, Jeff Lazarus and Meena Bansal discuss how this will roll out as we move ahead. It starts with Louise Campbell asking why there Allied Health Providers did not play a larger role in t...

Send us Fan Mail This conversation focuses on the Delphi process for a new MASLD nomenclature. It starts with Jeff Lazarus describing what a Delphi process is and how it worked here. Jeff and two other key players in this process, Maru Rinella and Meena Bansal, describe what they consider some of its greatest strengths as well as one thing they wish had worked out better. Jeff's description f...

Send us Fan Mail This conversation focuses on the issues and visions that led to the identified need for a new MASLD nomenclature. Maru Rinella and Jeff Lazarus discuss the original goals of the process and how focus broadened and shifted throughout. It starts with Maru Rinella describing what she terms “an existential crisis” for the field around a publication suggesting changing the name of the...

Send us Fan Mail The process of creating a new MASLD nomenclature for the condition formerly known as Fatty Liver Disease was a multi-year process with unique challenges and complications. Three leaders in the process, Maru Rinella, Jeff Lazarus and Meena Bansal, and patient advocate Mike Betel join Louise Campbell and Roger Green to discuss the process, transition and rollout. 00:00:00 - Surf&apo...

Send us Fan Mail This conversation is part of a March, 2023 interview between co-hosts Louise Campbell and Roger Green and Jeff McIntyre of Global Liver Institute, one of the guests on the S5 E2 panel. This particular conversation focuses largely on Jeff’s insights around the imminent anticipated drug approvals of obeticholic acid (which was withdrawn several months later) and resmetirom (whose PD...

Send us Fan Mail Leading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver Foundation) describe their respective organizations' priority 2024 MASH programs to co-hosts Louise Campbell and Roger Green. In this conversation, the advocates each describe their resp...

Send us Fan Mail Leading MASLD patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join Louise Campbell and Roger Green to explore the roles advocacy groups might play in supporting patient access through drug information, education and advocacy processes.  The...

Send us Fan Mail Leading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver Foundation) join Louise Campbell and Roger Green to discuss what Jeff calls "the second half" - the hard work on coding and patient access that will follow the first MASH drug approval. 

Send us Fan Mail Leading patient advocates Jeff McIntyre (Global Liver Institute), Milan Mishkovikj (European Liver Patients Association), Tony Villiotti (NASH kNOWledge) and Wayne Eskridge (Fatty Liver Foundation) discuss their expectations for life after the resmetirom PDUFA data and, with it, the potential for the first MASH drug approval, with Louise Campbell and Roger Green.  The conversation...

Send us Fan Mail 00:00:00 Surf's Up: Season 5 Episode 2 Co-hosts Louise Campbell and Roger Green sit with four leading MASLD patient advocates (Tony Villiotti of NASH kNOWledge, Wayne Eskridge of the Fatty Liver Foundation, Jeff McIntyre of the Global Liver Institute, and  Milan Mishkevikj of the European Liver Patients Association) to discuss their plans and actions for MASH patients in 2024...

Send us Fan Mail After a month off in January, SurfingMASH returns for the 2024 calendar year. In this last segment of Episode 1, the co-hosts explore the complexities surrounding advertising and accessibility of metabolic agents in the US market, with a particular focus on how these factors might influence public engagement and healthcare provider education. The tone of this segment demonstrates...

Send us Fan Mail After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group examines the explosion of telemarketer-driven consumer advertising for GLP-1 agents as anti-obesity medicines and asks what impact this might have on diagnosis, treatment and monitoring of MASH in the US.  Specifically, the participants discuss the potential impact and con...

Send us Fan Mail After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, the group explores the goal of provider and patient liver education, key goals for liver awareness and the potential for direct-to-consumer advertising of GLP-1s for weight loss to garble the "liver awareness" message.  The dialogue underscores the concern that the conveni...

Send us Fan Mail After a month off in January, SurfingMASH returns for the 2024 calendar year. In this conversation, Louise Campbell describes how VCTE can serve as a behavioral monitor, Roger Green reviews some changes in the podcast this year and the group begins to discuss why "liver awareness" should become an important concept.  As this conversation starts, a joke from Roger Green a...